<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Critical Appraisal: ADHD Drug Treatment and Adverse Outcomes (BMJ 2025;390:e083658)</title>
  <meta name="description" content="Critical appraisal of BMJ 2025 study emulating target trials to evaluate ADHD drug treatment and risks of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality." />
  <meta name="author" content="Generated by GPT-5 Assistant" />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <a class="skip-link" href="#main">Skip to content</a>
  <header class="site-header" role="banner">
    <div class="container header-inner">
      <h1 class="site-title">Critical Appraisal</h1>
      <div class="header-meta">
        <p class="study-title">
          ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials
        </p>
        <p class="citation">BMJ 2025;390:e083658 · doi: <a href="https://doi.org/10.1136/bmj-2024-083658" target="_blank" rel="noopener">10.1136/bmj-2024-083658</a></p>
      </div>
      <button id="themeToggle" class="btn" aria-pressed="false" aria-label="Toggle dark mode">Toggle theme</button>
    </div>
  </header>

  <nav class="toc container" aria-label="On this page">
    <details open>
      <summary>On this page</summary>
      <ol>
        <li><a href="#summary">Summary</a></li>
        <li><a href="#picos">PICOS</a></li>
        <li><a href="#methods">Methods appraisal</a></li>
        <li><a href="#results">Results</a></li>
        <li><a href="#biases">Bias and validity</a></li>
        <li><a href="#applicability">Applicability</a></li>
        <li><a href="#strengths-limitations">Strengths & limitations</a></li>
        <li><a href="#conclusion">Conclusion</a></li>
        <li><a href="#citation">Citation & license</a></li>
      </ol>
    </details>
  </nav>

  <main id="main" class="container" role="main">
    <section id="summary" class="card">
      <h2>Summary</h2>
      <p>
        Nationwide Swedish register data (2007–2020) were used to emulate per-protocol target trials in 148,581 people (ages 6–64) newly diagnosed with ADHD. Initiation and sustained use of ADHD medication within three months was associated with lower two-year rates of first events for suicidal behaviours (IRR 0.83), substance misuse (0.85), transport accidents (0.88), and criminality (0.87), but not accidental injuries (0.98). For recurrent events, rate reductions were observed for all five outcomes (range 0.75–0.96). Effects were generally larger among individuals with prior events and for stimulants versus non-stimulants.
      </p>
    </section>

    <section id="picos" class="card">
      <h2>PICOS</h2>
      <dl class="picos">
        <dt>Population</dt>
        <dd>Swedish residents aged 6–64 with incident ADHD (ICD-10 F90), 2007–2018; subcohorts aged ≥15 for transport accidents and criminality.</dd>
        <dt>Intervention</dt>
        <dd>Start ADHD medication within 3 months of diagnosis and remain on treatment (sustained use, per protocol analogue).</dd>
        <dt>Comparator</dt>
        <dd>No ADHD medication initiation during follow-up.</dd>
        <dt>Outcomes</dt>
        <dd>First and recurrent events over 2 years: suicidal behaviours, substance misuse, accidental injuries, transport accidents, criminality.</dd>
        <dt>Study design</dt>
        <dd>Target trial emulation using cloning, censoring, and inverse-probability-of-censoring weighting; weighted pooled logistic regression approximating IRR; bootstrapped CIs.</dd>
      </dl>
    </section>

    <section id="methods" class="card">
      <h2>Methods appraisal</h2>
      <ul>
        <li><strong>Design suitability</strong>: TTE framework aligns treatment strategies and follow-up, addressing immortal time bias and enhancing causal interpretability in observational data.</li>
        <li><strong>Confounding control</strong>: Extensive baseline and time-varying covariates in IPCW models; truncation at 99.5th percentile to limit extreme weights. Residual confounding remains possible (e.g., unmeasured severity, adherence, lifestyle).</li>
        <li><strong>Exposure definition</strong>: Per-protocol analogue (initiate within 3 months and sustain). Misclassification risk if dispensed ≠ consumed; likely biases toward null.</li>
        <li><strong>Outcome validity</strong>: National registers with high capture and reasonable PPV; may miss less severe outcomes not reaching medical/legal systems.</li>
        <li><strong>Analytic choices</strong>: Pooled logistic regression approximates IRR with discrete time; recurrent event approach allows ≥1 event/mo.</li>
        <li><strong>Sensitivity/negative control</strong>: Similar findings with 6-month grace and allowing drug switching; no association for type 1 diabetes negative control supports robustness.</li>
        <li><strong>Generalisability</strong>: High for Sweden and similar contexts; caution where diagnostic and prescribing practices differ.</li>
      </ul>
    </section>

    <section id="results" class="card">
      <h2>Results</h2>

      <h3>First events (per 1000 person-years)</h3>
      <div class="table-wrap" role="region" aria-labelledby="tbl-first">
        <table id="tbl-first">
          <caption>Weighted incidence rates and adjusted incidence rate ratios (IRR)</caption>
          <thead>
            <tr>
              <th scope="col">Outcome</th>
              <th scope="col">Initiation</th>
              <th scope="col">Non-initiation</th>
              <th scope="col">IRR (95% CI)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row">Suicidal behaviours</th>
              <td>14.5</td>
              <td>16.9</td>
              <td>0.83 (0.78–0.88)</td>
            </tr>
            <tr>
              <th scope="row">Substance misuse</th>
              <td>58.7</td>
              <td>69.1</td>
              <td>0.85 (0.83–0.87)</td>
            </tr>
            <tr>
              <th scope="row">Accidental injuries</th>
              <td>88.5</td>
              <td>90.1</td>
              <td>0.98 (0.96–1.01)</td>
            </tr>
            <tr>
              <th scope="row">Transport accidents</th>
              <td>24.0</td>
              <td>27.5</td>
              <td>0.88 (0.82–0.94)</td>
            </tr>
            <tr>
              <th scope="row">Criminality</th>
              <td>65.1</td>
              <td>76.1</td>
              <td>0.87 (0.83–0.90)</td>
            </tr>
          </tbody>
        </table>
      </div>

      <h3>Recurrent events (per 1000 person-years)</h3>
      <div class="table-wrap" role="region" aria-labelledby="tbl-recur">
        <table id="tbl-recur">
          <caption>Weighted incidence rates and adjusted incidence rate ratios (IRR)</caption>
          <thead>
            <tr>
              <th scope="col">Outcome</th>
              <th scope="col">Initiation</th>
              <th scope="col">Non-initiation</th>
              <th scope="col">IRR (95% CI)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row">Suicidal behaviours</th>
              <td>22.7</td>
              <td>24.3</td>
              <td>0.85 (0.77–0.93)</td>
            </tr>
            <tr>
              <th scope="row">Substance misuse</th>
              <td>166.1</td>
              <td>201.5</td>
              <td>0.75 (0.72–0.78)</td>
            </tr>
            <tr>
              <th scope="row">Accidental injuries</th>
              <td>119.4</td>
              <td>122.8</td>
              <td>0.96 (0.92–0.99)</td>
            </tr>
            <tr>
              <th scope="row">Transport accidents</th>
              <td>31.6</td>
              <td>37.2</td>
              <td>0.84 (0.76–0.91)</td>
            </tr>
            <tr>
              <th scope="row">Criminality</th>
              <td>111.3</td>
              <td>143.4</td>
              <td>0.75 (0.71–0.79)</td>
            </tr>
          </tbody>
        </table>
      </div>

      <h3>Subgroups and comparisons</h3>
      <ul>
        <li><strong>Prior events</strong>: Larger reductions among those with previous outcomes (e.g., suicidal behaviours IRR 0.79; criminality 0.85).</li>
        <li><strong>Age/sex</strong>: Greater reductions in adults for substance misuse and criminality; stronger reduction in first crime among females.</li>
        <li><strong>Drug class</strong>: Stimulants associated with lower rates than non-stimulants (e.g., first events IRR range ≈0.74–0.95).</li>
      </ul>
    </section>

    <section id="biases" class="card">
      <h2>Bias and validity considerations</h2>
      <ul>
        <li><strong>Immortal time</strong>: Addressed via cloning, grace period alignment, and censoring.</li>
        <li><strong>Selection bias</strong>: Mitigated with IPCW using rich time-varying covariates; truncation reduces variance inflation.</li>
        <li><strong>Residual confounding</strong>: Possible (severity, health behaviours, adherence); negative control outcome (type 1 diabetes) suggests limited bias.</li>
        <li><strong>Measurement error</strong>: Dispensing ≠ consumption may attenuate effects.</li>
        <li><strong>Outcome capture</strong>: Severe events well captured; milder events may be under-ascertained.</li>
        <li><strong>External validity</strong>: Context-specific prescribing (e.g., methylphenidate predominance) may limit transportability.</li>
      </ul>
    </section>

    <section id="applicability" class="card">
      <h2>Applicability</h2>
      <ul>
        <li><strong>Patients</strong>: Results reflect routine clinical populations across a wide age span.</li>
        <li><strong>Clinicians</strong>: Supports initiating and sustaining ADHD medication for broad functional outcomes, with stimulants generally first-line.</li>
        <li><strong>Policy</strong>: Findings inform benefit–risk debates and essential medicine lists; underscores need for pragmatic trials capturing functional outcomes.</li>
      </ul>
    </section>

    <section id="strengths-limitations" class="card">
      <h2>Strengths and limitations</h2>
      <ul>
        <li><strong>Strengths</strong>: National coverage; TTE design; extensive covariate adjustment; sensitivity and negative control analyses; broad age range.</li>
        <li><strong>Limitations</strong>: No data on non-drug therapies or dose; potential exposure misclassification; limited capture of less severe outcomes; uncertain generalisability beyond similar healthcare contexts.</li>
      </ul>
    </section>

    <section id="conclusion" class="card emphasis">
      <h2>Conclusion</h2>
      <p>
        ADHD medication initiation and sustained use were associated with meaningful reductions in several serious outcomes over two years, with consistent benefits for recurrent events and comparatively stronger effects for stimulants. Estimates likely reflect conservative effects for the full ADHD population in routine care.
      </p>
    </section>

    <section id="citation" class="card">
      <h2>Citation & license</h2>
      <p>
        Original article: Zhang L, Zhu N, Sjölander A, et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. <em>BMJ</em>. 2025;390:e083658. doi: <a href="https://doi.org/10.1136/bmj-2024-083658" target="_blank" rel="noopener">10.1136/bmj-2024-083658</a>.
      </p>
      <p>
        This appraisal site is provided under CC BY 4.0. Cite the original authors and link to the DOI.
      </p>
      <p>
        Correspondence: Z Chang &lt;<a href="mailto:zheng.chang@ki.se">zheng.chang@ki.se</a>&gt;; ORCID 0000-0002-8087-1417.
      </p>
      <p>
        Source code: <a href="https://osf.io/y7fhj/" target="_blank" rel="noopener">Open Science Framework</a> (article code/resources).
      </p>
    </section>
  </main>

  <footer class="site-footer" role="contentinfo">
    <div class="container">
      <p>
        © <span id="year"></span> Critical Appraisal. Built for educational purposes. Not medical advice.
      </p>
    </div>
  </footer>

  <script src="script.js"></script>
</body>
</html>
